Detailed Information
Cited 0 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
Which biomarker is useful to evaluate as a treatment outcome in spondyloarthritis?
- Authors
- Lee, Sang-Hoon; Kim, Tae Hwan
- Issue Date
- Aug-2009
- Publisher
- Bentham Science Publishers
- Keywords
- Ankylosing spondylitis; Biomarkers; Spondyloarthritis; TNF-alpha blockade
- Citation
- Current Rheumatology Reviews, v.5, no.3, pp 165 - 168
- Pages
- 4
- Indexed
- SCOPUS
- Journal Title
- Current Rheumatology Reviews
- Volume
- 5
- Number
- 3
- Start Page
- 165
- End Page
- 168
- ISSN
- 1573-3971
1875-6360
- Abstract
- Although the etiology of ankylosing spondylitis is unknown, it is necessary to develop tools for evaluating the patient response to the new therapeutic drugs. AS is mediated by chronic inflammation and characterized by bone destruction and formation. Recently, tumor necrosis factor-alpha (TNF-alpha) blockade has been widely used for treatment of AS, and the patient response is evaluated by examining the levels of various biomarkers such as matrix metalloproteinases (MMPs), interleukins (ILs), and vascular endothelial growth factor (VEGFs). This review discusses the recent studies suggesting candidate biomarkers for evaluation of the response to treatment and the joint remodeling markers.
- Files in This Item
- Go to Link
- Appears in
Collections - 서울 의과대학 > 서울 내과학교실 > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Related Researcher
- Kim, Tae Hwan
- 서울 의과대학 (DEPARTMENT OF INTERNAL MEDICINE)